Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

This retrospective cohort study from Israel examined the incidence of myocarditis following the BNT162b2 mRNA Covid-19 vaccine. Active surveillance was conducted between December 2020 and May 2021. Of the 283 confirmed myocarditis cases, 142 were associated with vaccination, with 136 classified as definite or probable. The risk was highest after the second dose among males aged 16–19, presenting typically with mild symptoms. Standardized incidence ratios and rate ratios confirmed increased incidence in vaccinated individuals versus historical and unvaccinated cohorts. These findings support a temporal association, particularly in young males, and underscore the need for continued safety monitoring.

This retrospective cohort study from Israel examined the incidence of myocarditis following the BNT162b2 mRNA Covid-19 vaccine. Active surveillance was conducted between December 2020 and May 2021. Of the 283 confirmed myocarditis cases, 142 were associated with vaccination, with 136 classified as definite or probable. The risk was highest after the second dose among males aged 16–19, presenting typically with mild symptoms. Standardized incidence ratios and rate ratios confirmed increased incidence in vaccinated individuals versus historical and unvaccinated cohorts. These findings support a temporal association, particularly in young males, and underscore the need for continued safety monitoring.